These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

122 related items for PubMed ID: 2166145

  • 21. Experience of a German multicenter study group with ifosfamide in small cell lung cancer.
    Havemann K, Wolf M, Drings P, Hans K, Schroeder M, Holle R, Flechtner H, Goerg R, Becker H.
    Semin Oncol; 1989 Feb; 16(1 Suppl 3):9-18. PubMed ID: 2539648
    [Abstract] [Full Text] [Related]

  • 22. A phase II study on lonidamine combined with cisplatin and etoposide in the treatment of advanced non-small cell bronchogenic carcinoma (NSCBC).
    Lelli G, Guaraldi M, Canova N, Casadio M, Pannuti F.
    J Chemother; 1990 Dec; 2(6):401-4. PubMed ID: 1965508
    [Abstract] [Full Text] [Related]

  • 23. Cisplatin plus etoposide consolidation following cyclophosphamide, doxorubicin, and vincristine in limited small-cell lung cancer.
    Einhorn LH, Crawford J, Birch R, Omura G, Johnson DH, Greco FA.
    J Clin Oncol; 1988 Mar; 6(3):451-6. PubMed ID: 2832549
    [Abstract] [Full Text] [Related]

  • 24. Prolonged, alternating chemotherapy for extensive small cell lung cancer. A Southwest oncology Group study.
    Livingston RB, Crowley JJ, Thompson T, Williamson SK, Meyers FJ, O'Rourke T, Neefe JR.
    Cancer; 1993 Jun 01; 71(11):3509-13. PubMed ID: 8387881
    [Abstract] [Full Text] [Related]

  • 25. Granulocyte-macrophage colony-stimulating factor increases dose intensity of chemotherapy in small cell lung cancer. Relationship between clinical results, peripheral blood cell modifications, and bone marrow kinetics.
    Paccagnella A, Favaretto A, Riccardi A, Danova M, Ghiotto C, Giordano M, Pappagallo G, Comis S, Panozzo M, Chieco-Bianchi L.
    Cancer; 1993 Aug 01; 72(3):697-706. PubMed ID: 8392903
    [Abstract] [Full Text] [Related]

  • 26. Etoposide combined with cyclophosphamide plus vincristine compared with doxorubicin plus cyclophosphamide plus vincristine and with high-dose cyclophosphamide plus vincristine in the treatment of small-cell carcinoma of the lung: a randomized trial of the Bristol Lung Cancer Study Group.
    Hong WK, Nicaise C, Lawson R, Maroun JA, Comis R, Speer J, Luedke D, Hurtubise M, Lanzotti V, Goodlow J.
    J Clin Oncol; 1989 Apr 01; 7(4):450-6. PubMed ID: 2538577
    [Abstract] [Full Text] [Related]

  • 27. A phase II trial of cyclophosphamide, etoposide, and cisplatin with combined chest and brain radiotherapy in limited small-cell lung cancer: a Cancer and Leukemia Group B Study.
    Kwiatkowski DJ, Propert KJ, Carey RW, Choi N, Green M.
    J Clin Oncol; 1987 Dec 01; 5(12):1874-9. PubMed ID: 2824709
    [Abstract] [Full Text] [Related]

  • 28. A phase II study of all-trans-retinoic acid plus cisplatin and etoposide in patients with extensive stage small cell lung carcinoma: an Eastern Cooperative Oncology Group Study.
    Kalemkerian GP, Jiroutek M, Ettinger DS, Dorighi JA, Johnson DH, Mabry M.
    Cancer; 1998 Sep 15; 83(6):1102-8. PubMed ID: 9740074
    [Abstract] [Full Text] [Related]

  • 29. Concurrent cisplatin, prolonged oral etoposide, and vincristine plus chest and brain irradiation for limited small cell lung cancer: a phase II study of the Southwest Oncology Group (SWOG-9229).
    Thomas CR, Giroux DJ, Stelzer KJ, Craig JB, Laufman LR, Taylor SA, Goodwin JW, Crowley JJ, Livingston RB.
    Int J Radiat Oncol Biol Phys; 1998 Mar 15; 40(5):1039-47. PubMed ID: 9539558
    [Abstract] [Full Text] [Related]

  • 30. Phase I study of weekly alternating therapy with irinotecan/cisplatin and etoposide/cisplatin for patients with small-cell lung cancer.
    Johnson FM, Kurie JM, Peeples BO, Lee JJ, Feng L, Pisters KM, Fossella FV, Papadimitrakopoulou VA, Blumenschein GR, Komaki R, Glisson BS.
    Clin Lung Cancer; 2003 Jul 15; 5(1):40-5. PubMed ID: 14596703
    [Abstract] [Full Text] [Related]

  • 31. A randomized study of chemotherapy with cisplatin plus etoposide versus chemoendocrine therapy with cisplatin, etoposide and the pineal hormone melatonin as a first-line treatment of advanced non-small cell lung cancer patients in a poor clinical state.
    Lissoni P, Paolorossi F, Ardizzoia A, Barni S, Chilelli M, Mancuso M, Tancini G, Conti A, Maestroni GJ.
    J Pineal Res; 1997 Aug 15; 23(1):15-9. PubMed ID: 9379341
    [Abstract] [Full Text] [Related]

  • 32. Cisplatin, ifosfamide, and prolonged oral etoposide in the treatment of patients with extensive small cell lung carcinoma.
    Glisson B, Lee JS, Palmer J, Fossella F, Shin DM, Murphy WK, Perez-Soler R, Hong WK.
    Cancer; 1998 Jan 15; 82(2):301-8. PubMed ID: 9445186
    [Abstract] [Full Text] [Related]

  • 33. Second-line chemotherapy in recurrent small cell lung cancer. Results from a crossover schedule after primary treatment with cisplatin and etoposide (EP-regimen) or cyclophosphamide, epirubicin, and vincristin (CEV-regimen).
    Sundstrøm S, Bremnes RM, Kaasa S, Aasebø U, Aamdal S, Norwegian Lung Cancer Study Group.
    Lung Cancer; 2005 May 15; 48(2):251-61. PubMed ID: 15829326
    [Abstract] [Full Text] [Related]

  • 34. Combination chemotherapy with vincristine, epirubicin and cyclophosphamide in small cell lung carcinoma. Polish Lung Cancer Cooperative Group.
    Jassem J, Karnicka-Młodkowska H, Drozd-Lula M, Strug A, Pilarska-Machowicz A, Michalski A, Kowal E, Moś-Antkowiak R, Zych J.
    Eur J Cancer; 1992 May 15; 28(2-3):473-6. PubMed ID: 1317199
    [Abstract] [Full Text] [Related]

  • 35. A phase II trial of cisplatin and irinotecan alternating with doxorubicin, cyclophosphamide and etoposide in previously untreated patients with extensive-disease small-cell lung cancer.
    Tabata M, Kiura K, Okimoto N, Segawa Y, Shinkai T, Yonei T, Kuyama S, Harita S, Hotta K, Ueoka H, Tanimoto M.
    Cancer Chemother Pharmacol; 2007 Jun 15; 60(1):1-6. PubMed ID: 17393168
    [Abstract] [Full Text] [Related]

  • 36. [A comparative randomized phase II study of CDDP, CDDP-carboquone (CQ) and CDDP-etoposide as second-line chemotherapy in small cell lung cancer (SCLC)].
    Kobayashi K, Hino M, Kurane S, Yano T, Niitani H, Yamano Y, Hasegawa K, Tuboi E.
    Gan To Kagaku Ryoho; 1989 Feb 15; 16(2):207-12. PubMed ID: 2537605
    [Abstract] [Full Text] [Related]

  • 37. Prospective randomized comparison of high-dose and standard-dose etoposide and cisplatin chemotherapy in patients with extensive-stage small-cell lung cancer.
    Ihde DC, Mulshine JL, Kramer BS, Steinberg SM, Linnoila RI, Gazdar AF, Edison M, Phelps RM, Lesar M, Phares JC.
    J Clin Oncol; 1994 Oct 15; 12(10):2022-34. PubMed ID: 7931470
    [Abstract] [Full Text] [Related]

  • 38. [Dose-response effect of drugs in the chemotherapy of small-cell bronchial carcinoma].
    Kostić D, Jelić S, Radulović S.
    Srp Arh Celok Lek; 2000 Oct 15; 128(3-4):75-9. PubMed ID: 10932613
    [Abstract] [Full Text] [Related]

  • 39. Etoposide plus cisplatin with or without the combination of 4'-epidoxorubicin plus cyclophosphamide in treatment of extensive small-cell lung cancer: a French Federation of Cancer Institutes multicenter phase III randomized study.
    Pujol JL, Daurès JP, Rivière A, Quoix E, Westeel V, Quantin X, Breton JL, Lemarié E, Poudenx M, Milleron B, Moro D, Debieuvre D, Le Chevalier T.
    J Natl Cancer Inst; 2001 Feb 21; 93(4):300-8. PubMed ID: 11181777
    [Abstract] [Full Text] [Related]

  • 40. A phase I-II study of sequential infusion VP-16 and cisplatin therapy in advanced lung cancer.
    Krook JE, Jett JR, Little C.
    Am J Clin Oncol; 1989 Apr 21; 12(2):114-7. PubMed ID: 2539716
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.